Business
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company
About this update from Artiva Biotherapeutics, Inc.
[{"type":"text","content":"Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from discovery through FDA approval and commercialization, including PREZISTA® and INTELENCE® SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings more than two decades of senior leadership and drug development experience, with a track record of advancing therapies from discovery through approval and commercialization, to support Artiva as it advances AlloNK® in autoimmune diseases and prepares for registrational development in refractory rheumatoid arthritis (RA). “I am thrilled to have the opportunity to work with Diego again, as we did at Vividion, and to welcome him into this leadership role at such an important time for Artiva,” said Fred Aslan, M.D., Chief Executive Officer of Artiva. “Diego combines strategic, scientific and clinical judgement with a proven ability to build organizations and advance innovative therapies. These qualities will be critical as we advance AlloNK toward registrational development in refractory RA, while continuing to build a company capable of bringing a potentially transformative therapy to patients. With recent FDA alignment on a potential registrational path, Diego’s experience and leadership will be instrumental as we prepare for and execute our Phase 3 trial in refractory RA, advance AlloNK across multiple autoimmune diseases and file our first successful BLA for AlloNK in 2029.” “Having served on Artiva’s Board of Directors for the past two years, I have seen firsthand the promise of AlloNK and the dedication of the team advancing it,” said Dr. Miralles. “Artiva is at a pivotal moment, with a therapeutic approach that has the potential to meaningfully change how autoimmune diseases are treated. AlloNK’s potential to deliver deep B-cell depletion in a consistent, scalable and outpatient-ready format is exactly the kind of innovation that could expan...